Castleark Management LLC Mirati Therapeutics, Inc. Transaction History

Castleark Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	BUY	$59.5 - $86.7 $1.46 Million - $2.13 Million	24,560 New	24,560 $1.72 Million
Q1 2021 May 14, 2021	SELL	$158.92 - $221.61 $4.12 Million - $5.74 Million	-25,918 Closed	0 $0
Q4 2020 Feb 17, 2021	SELL	$162.05 - $240.27 $3.32 Million - $4.93 Million	-20,510 Reduced 44.18%	25,918 $5.69 Million
Q3 2020 Nov 16, 2020	SELL	$113.26 - $167.27 $14,950 - $22,079	-132 Reduced 0.28%	46,428 $7.71 Million
Q2 2020 Aug 14, 2020	SELL	$72.01 - $120.39 $37,445 - $62,602	-520 Reduced 1.1%	46,560 $5.32 Million
Q1 2020 May 13, 2020	BUY	$69.78 - $116.21 $3.29 Million - $5.47 Million	47,080 New	47,080 $3.62 Million

3.57M

36.6K

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

Get notified when there are updates to the investment portfolio of Castleark Management LLC, based on Form 13F filings with the SEC.

Stay updated on Castleark Management LLC with notifications on news.